8 February 2019
Australian Securities Exchange (ASX) Announcement
- Sensera expands its precision microfabrication capabilities to deliver commercially viable Lab-on-a-Chip and Organ-on-a-Chip diagnostics
- New technology empowers Sensera clients to achieve rapid, sensitive investigation of nucleic acid samples, DNA and RNA, and proteins
- Transformative technology in the microfluidics industry, which is growing at a 15% CAGR in a US$5B global market set to triple in the next 7 years
Sensera Limited (ASX: SE1, “Sensera” or “the Company”), an Internet of Things (IoT) solution provider that delivers sensor-based products transforming real-time data into meaningful information, action and value, is pleased to announce that its subsidiary Sensera Inc. (MicroDevices), a designer and manufacturer of specialised high-performance sensors and modules, has expanded its capabilities to include chips for Point-of-Care and Lab-on-a-Chip applications, as well as droplet microfluidic devices. The Company has achieved this expansion of microfluidic product applications in partnership with newly engaged customers.
Sensera has recently developed Point-of-Care and Lab-on-a-Chip devices using microchannels, which are coupled with chambers or wells filled with reagents to detect and measure specific biomarkers for diagnostic purposes. They can also be used for rapid and sensitive investigation of nucleic acid samples, DNA and RNA, and proteins.
Silicon chips and etched microfluidic channels with hermetically bonded glass cap
Glass etched chip with hermetically bonded glass cap with wells
Marisel De Jesus Vega, Program Manager at Sensera, said:
“Sensera is a leader in the fabrication of precision silicon- and glass-based micro-molds for customers – extremely small, high-precision components. We are pleased to have developed the capability to also fabricate microfluidic devices targeting Point-of-Care and Lab-on-a-Chip applications, having very challenging dimensional and defect tolerances. Sensera has invested years in process optimisation and our adherence to a stringent quality management system empowers us to produce this demanding technology cost effectively and with the highest quality.”
Microfluidics is one of the common tools used in life sciences research for amplification and manipulation of genetic materials such as DNA or RNA. The adoption of microfluidics over traditional diagnostic methods is growing at a compound annual growth rate (CAGR) of almost 15%. Currently, this represents a US$5B global market, which is projected to reach $15B by 2026 (according to Transparency Market Research Pvt. Ltd.). This growth is likely to be driven by rising demand for Point-of-Care devices enabled by miniaturisation of microfluidic chips, the associated cost reductions, and the rapid return on investment.
Dr. Richard Novak, Senior Staff Engineer at Harvard University’s Wyss Institute for Biologically Inspired Engineering (a Sensera client) said:
“The Wyss Institute has developed a suite of Organ, Lab-on-a-Chip devices and applications to enhance safety and efficacy of compounds in the pharmaceutical pipeline, discover novel therapeutics, and explore health and disease at altogether new levels of analysis. Sensera has been a key partner in enabling precision microfabrication of our Organ-on-a-Chip devices and technologies.”
Ralph Schmitt, CEO of Sensera, said:
“Sensera’s charter is to be a high service level, customer-driven, customised micro component supplier. In the world of life sciences, it is becoming increasingly complex and challenging for developers to design and build commercially viable solutions. Sensera is working together with customers to develop this intricate technology, while substantially streamlining functionality and costs. Building end products that will get deployed in real-life medical applications is a key focus to driving revenue growth in FY20 and beyond.”